Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075608 · ClinicalTrials.gov registry record · Phase 2
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
A Phase 2 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00075608 is a Phase 2 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT00075608, a Phase 2 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having a stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing the number of plasma cells, the disease may progress more slowly. PURPOSE: This phase II trial is studying how well autologous stem cell transplant works in treating patients with persistent or recurrent primary systemic (AL) amyloidosis.
Interventions
- PROCEDURE autologous stem cell transplantation
- DRUG melphalan
- BIOLOGICAL filgrastim
- PROCEDURE stem cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2001-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075608
The ClinicalTrials.gov registry entry for NCT00075608 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which autologous stem cell transplantation is the first listed.
NCT00075608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075608 about?
NCT00075608 is a clinical study titled "2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having a stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given ...
What is the current status of trial NCT00075608?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2001-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00075608?
The interventions under investigation include: autologous stem cell transplantation (PROCEDURE), melphalan (DRUG), filgrastim (BIOLOGICAL), stem cell infusion (PROCEDURE).
Who is sponsoring clinical trial NCT00075608?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.